4.12

2.60% -0.11

After Hours: 4.13 0.010 +0.24%

Aquestive Therapeutics Inc (AQST)

Overview News Price History Option Chain Financials Discussions Forecast

Aquestive Therapeutics Inc stock is traded at $4.12, with a volume of 892.37K. It is down -2.60% in the last 24 hours and down -0.72% over the past month. Aquestive Therapeutics Inc is a specialty pharmaceutical company engaged in developing and commercializing differentiated products to meet medical needs. Its later-stage product pipeline focuses on the treatment of diseases of the Central Nervous System (CNS), and an earlier-stage pipeline for the treatment of severe allergic reactions, including anaphylaxis. Its commercial product portfolio includes Suboxone, Emylif, Ondif, and Sympazan. The product pipeline includes Libervant Buccal Film, AQST-108. The majority of its revenue comes from the United States.

Previous Close:

$4.23

Open:

$4.26

24h Volume:

892.37K

Relative Volume:

0.51

Market Cap:

$516.85M

Revenue:

$44.55M

Net Income/Loss:

$-83.78M

P/E Ratio:

-5.2997

EPS:

-0.7774

Net Cash Flow:

$-52.99M

1W Performance:

-1.20%

1M Performance:

-0.72%

6M Performance:

-27.97%

1Y Performance:

+79.91%

1-Day Range:

$4.115

$4.29

1-Week Range:

$3.98

$4.29

52-Week Range:

$2.222

$7.55

Aquestive Therapeutics Inc Stock (AQST) Company Profile

Name

Aquestive Therapeutics Inc

Sector

Healthcare (1108)

Industry

Drug Manufacturers - Specialty & Generic (86)

Phone

908-941-1900

Address

30 TECHNOLOGY DRIVE, WARREN, NJ

Employee

147

Twitter

Next Earnings Date

2026-05-13

Latest SEC Filings

AQST's Discussions on Twitter

Compare AQST vs TAK, HLN, TEVA, ZTS, UTHR

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
AQST Aquestive Therapeutics Inc	4.12	530.65M	44.55M	-83.78M	-52.99M	-0.7774
TAK Takeda Pharmaceutical Co Adr	16.25	52.07B	29.91B	1.30B	3.49B	0.4056
HLN Haleon Plc Adr	9.29	41.28B	14.54B	2.22B	2.58B	0.4871
TEVA Teva Pharmaceutical Industries Ltd Adr	34.07	39.78B	17.53B	1.58B	444.18M	1.3457
ZTS Zoetis Inc	81.32	33.57B	9.51B	2.64B	2.14B	6.0361
UTHR United Therapeutics Corp	568.43	24.02B	3.17B	1.29B	1.01B	27.09

Aquestive Therapeutics Inc Stock (AQST) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Apr-24-26	Resumed	Oppenheimer	Outperform
Jun-02-25	Resumed	Oppenheimer	Outperform
Dec-17-24	Initiated	Cantor Fitzgerald	Overweight
May-10-24	Initiated	Leerink Partners	Outperform
Apr-11-24	Initiated	Piper Sandler	Overweight
Mar-28-24	Initiated	Raymond James	Outperform
Apr-07-21	Resumed	RBC Capital Mkts	Outperform
Apr-22-19	Initiated	H.C. Wainwright	Buy
Jan-03-19	Initiated	Lake Street	Buy
Aug-20-18	Initiated	JMP Securities	Mkt Outperform
Aug-20-18	Initiated	RBC Capital Mkts	Outperform

View All

Aquestive Therapeutics Inc Stock (AQST) Latest News

May 22, 2026

Aquestive Therapeutics CEO sells $35,413 in company stock By Investing.com - Investing.com South Africa

May 18, 2026

Aquestive Therapeutics CEO sells $35,413 in company stock - Investing.com UK

May 18, 2026

May 17, 2026

PRN_FinancialWrapper - FinancialContent

May 17, 2026

May 16, 2026

Aquestive secures $150 million debt facility with Oaktree By Investing.com - Investing.com Nigeria

May 16, 2026

Aquestive targets Q3 FDA resubmission for Anaphylm and projects >$150M cash at launch - MSN

May 16, 2026

A Quick Look at Today's Ratings for Aquestive Therapeutics(AQST.US), With a Forecast Between $6 to $9 - Moomoo

May 16, 2026

Analysts Offer Insights on Healthcare Companies: Aquestive Therapeutics (AQST) and Ardent Health Partners, Inc. (ARDT) - The Globe and Mail

May 16, 2026

May 15, 2026

Analysts Are Bullish on These Healthcare Stocks: Aquestive Therapeutics (AQST), Monopar Therapeutics Inc (MNPR) - The Globe and Mail

May 15, 2026

All News about Aquestive Therapeutics, Inc.Common Stock - The Chronicle-Journal

May 15, 2026

Lake Street Maintains Aquestive Therapeutics(AQST.US) With Buy Rating, Maintains Target Price $6 - Moomoo

May 15, 2026

Aquestive Says It’s on Track to Launch Anaphylm Studies for FDA - Allergic Living

May 15, 2026

Analysts Have Made A Financial Statement On Aquestive Therapeutics, Inc.'s (NASDAQ:AQST) First-Quarter Report - Moomoo

May 15, 2026

The Aquestive Therapeutics, Inc. (NASDAQ:AQST) First-Quarter Results Are Out And Analysts Have Published New Forecasts - Yahoo Finance

May 15, 2026

Aquestive Therapeutics, Inc. (NASDAQ:AQST) Q1 2026 Earnings Call Transcript - Insider Monkey

May 15, 2026

Citizens reiterates Aquestive stock rating on Anaphylm progress By Investing.com - Investing.com South Africa

May 15, 2026

Citizens reiterates Aquestive stock rating on Anaphylm progress - Investing.com

May 15, 2026

May 14, 2026

Aquestive Therapeutics Signals Momentum In Earnings Call - TipRanks

May 14, 2026

symbol__ Stock Quote Price and Forecast - CNN

May 14, 2026